What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.

The article discusses the role of Hypoxia-inducible factor-prolyl hydroxylase (HIF-PHIs) inhibitors in changing the management of iron in end-stage renal disease (ESRD). HIF-PHIs are noted to initiate some of the mechanisms triggered by hypoxia which can lead to downstream responsive pathways under the conditions of normal actual tissue-oxygen tensions.